To improve the expression levels of transgenes in malignant hematopoietic cells, we developed a novel adenoviral-alphavirus hybrid vector Ad5/F11p-SFV-GFP that contains a Semliki Forest Virus (SFV) replicon and chimeric fibers of Ad5 and Ad11p. Ad5/F11p-SFV-GFP infected 495% of K562, U937 or Jurkat cells and 23.65% of HL-60 cells, and led to moderate Enhanced Green Fluorescent Protein (EGFP) transgene expression intensity. The infection efficiency of Ad5/F11p-SFV-GFP in primary human leukemia cells ranged from 9.34-89.63% (median, 28.58%) at a multiplicity of infection (MOI) of 100, compared with only 3.37-44.54% (median, 10.42%) in cells infected by Ad5/F11p-GFP. Importantly, Ad5/F11p-SFV-GFP led to a significantly higher transgene expression level in primary leukemia cells, as indicated by the relative fluorescence intensity, compared to cells infected with Ad5/F11p-GFP. The increased expression of EGFP in Ad5/F11p-SFV-GFP-infected cells was associated with the accumulation of abundant subgenomic mRNA. Additionally, infection of K562, U937 or Jurkat cells by Ad5/F11p-SFV-GFP was significantly inhibited by blocking CD46 receptor; however, other factors may affect the gene-transfer efficiency of Ad5/F11p-SFV-GFP in primary leukemia cells. In conclusion, we successfully developed a novel adenoviral-alphavirus hybrid vector with RNA replicon features, which represents a promising vector for gene modifications during the production of cell-based vaccines for leukemia patients.
INTRODUCTION
The transduction efficiencies of viral gene delivery vectors are crucial for both gene therapy and basic experimental studies. [1] [2] [3] Retroviral vectors and lentiviral vectors can stably integrate into the host-cell genome and are instrumental tools for the genetic modification of hematopoietic cells. However, the adverse events documented in human clinical trials and animal models of retroviral vector-mediated gene transfer clearly indicate that insertional mutagenesis is a definite risk factor that needs to be accounted for when designing gene therapy trials. [4] [5] [6] Adenoviruses do not lead to genotoxicity due to insertion of viral DNA into the chromosomes of the host cells, and adenoviruses have been widely applied in gene therapy. However, hematopoietic cells such as primary hematopoietic stem cells, lymphocytes and myeloid cells are relatively resistant to adenoviral infection. Recently, several Ad5-based retargeting vectors such as Ad5F11p and Ad5/35 have been developed to improve the efficiency of transduction of hematopoietic cells. [7] [8] [9] However, the expression levels of the transgenes expressed by these vectors in transduced hematopoietic cells remains low; therefore, these vectors need to be improved.
The alphavirus vector has received considerable attention as it can express high levels of heterologous proteins. 10, 11 The key component of the alphavirus that drives high levels of transgene expression is the RNA replicase (Rep) complex, encoded by the viral nonstructural genes (NsPs). Upon transfecting alphavirus vectors into cells, Rep is translated and the vector RNA is copied into a negative-stranded RNA, which is used as template for amplification of the vector RNA. Rep can recognize a subgenomic promoter in the negative-stranded RNA, which generates a smaller subgenomic RNA, which in turn is translated to produce the heterologous protein. 11 Various alphavirus-based vectors have been developed, such as the Semliki Forest Virus (SFV) replicon, in which the genes coding for viral structural proteins have been substituted by a transgene. [11] [12] [13] Alphavirus vectors can infect a wide range of cells, and have a broad tropism. However, their gene-transfer efficiency is relatively low in hematopoietic cells. 14 To improve the expression of transgenes delivered by alphaviral vectors in hematopoietic cells, we developed an adenoviralalphavirus hybrid vector that contains a recombinant SFV replicon sequence under the transcriptional control of the hematopoietic cell-specific promoter CD11Ap 15 ( Figure 1a ). In this construct, the SFV replicon contains the Enhanced Green Fluorescent Protein (EGFP) gene driven by the SFV subgenomic promoter. We evaluated the gene transfer, expression efficiency and mechanism of action of this retargeted adenovirus in a variety of malignant hematopoietic cells, including cell lines and primary human leukemia cells.
MATERIALS AND METHODS

Plasmids, cell lines and primary cells
Ad5/F11p-E4orf3 was an Ad5/F11p 9 -based bone plasmid and was reconstructed by deletion of the E4 region (except for orf3).
The human leukemic cell lines K562, U937, Jurkat and HL-60 were maintained with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) and 293Cre4 cells (Microbix Biosystem, Mississauga, ON, Canada) were propagated in alpha-MEM medium supplemented with 10% FBS and 0.4 mg ml À 1 G418. The bone marrow samples and peripheral blood samples used in this study were obtained from patients undergoing diagnostic procedures at Beijing 307 Hospital. Informed consent was obtained from each patient. The patients were diagnosed with acute myelogenous leukemia (n ¼ 4), chronic myelogenous leukemia (n ¼ 3), acute lymphocytic leukemia (n ¼ 2) or chronic lymphocytic leukemia (n ¼ 1). Mononuclear cells were isolated from heparinized samples by centrifugation through a Ficoll-Hypaque density gradient (Amersham Biosciences, Piscataway, NJ, USA), and then the mononuclear cells were resuspended in Iscove's modified Dulbecco medium containing 10% FBS.
Construction of the alphavirus-adenovirus hybrid vector pAd5/F11p-SFV-GFP CD11Ap, NsPs, EGFP and SV40 polyA were inserted into the multiple cloning site of the pShuttle plasmid (Stratagene, Cedar Creek, TX, USA) to generate pShuttle-CD11Ap-SFV-GFP (pSh-SFV-GFP). Initially, the fragment containing CD11Ap was cloned into the alphavirus replicon vector pSFV1 to replace the SP6 RNA Polymerase promoter. Secondly, SV40 polyA and EGFP were inserted into the SpeI and BamHI sites of pSFV-CD11Ap, respectively. The CD11Ap-EFGP-SV40 poly A fragment (9704 bp) was obtained by digesting the plasmid with AscI, and then the CD11Ap-EFGP-SV40 poly A fragment was inserted into pShuttle using AscI. The plasmid pAd5/F11p-SFV-GFP, the genomic plasmid of the hybrid vector, was generated by homologous recombination of pSh-SFV-GFP and pAd5/ F11p-E4orf3 in Escherichia coli strain BJ5183 using a standard method. Rescue and identification of the alphavirus-adenovirus hybrid vector Ad5/F11p-SFV-GFP
The plasmid pAd5/F11p-SFV-GFP was linearized using PacI and transfected into 293Cre4 cells using the phosphate coprecipitation kit (Promega, Madison, WI, USA) following the manufacturer's instructions. A multiplicity of infection (MOI) of 5 Ad5/F11p-HV, a helper adenovirus suitable for the Cre-Loxp system, was added to the cells 24 h after transfection with pAd5/ F11p-SFV-GFP. Following the cytopathic effect, Ad5/F11p-SFV-GFP was collected and expanded in 293Cre4 cells using a MOI of 1 for Ad5/F11p-HV. The genomic DNA was extracted from 293Cre4 cells and incorporation of Ad5/F11p-SFV-GFP plasmid was confirmed by PCR using the following primers:
9 EGFP: sense 5 0 -TGACCACAACCAGCACCA-3 0 and anti-sense For real-time PCR, the cells were collected at 24 h or 48 h post infection, total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and cDNA was synthesized using M-MLV Reverse Transcriptase (Promega). Quantitative PCR was performed (as described above) using the following primers: NsP: 
Analysis of CD46 expression and gene-transfer efficiency in hematopoietic cells
Analysis of CD46 expression in hematopoietic cells. Cell lines or freshly isolated primary leukemic cells were incubated with a phycoerythrinconjugated mouse anti-human CD46 monoclonal antibody (Ab) (clone 344519; R&D Systems, Minneapolis, MN, USA) for 30 min and then analyzed by flow cytometry.
Infection blocking studies. K562, U937 and Jurkat cells were suspended in PBS containing 1% FCS at a density of 1 Â 10 6 cells per ml, then 50 ml aliquots were placed in microfuge tubes. Different concentrations of purified mouse anti-CD46 Ab (clone MEM-258; BioLegend, San Diego, CA, USA) were added to the tubes. The cells were incubated at 37 1C for 30 min, mixed by brief vortexing every 10 min, and then 10-ml aliquots of Ad5/F11p-SFV-GFP diluted in PBS containing 1% FCS were added. The cells, virus and Ab mixtures were incubated at 37 1C for 60 min and mixed by brief vortexing every 15 min. The Ab-virus complexes were removed by washing with PBS, then the cells were suspended in 300 ml RPMI-1640 medium containing 10% FCS, plated in 48-well plates and GFP expression was analyzed at 48 h post infection using FACS.
Optimization of conditions for hybrid vector infection
Cell density. U937 cells at a density of 1.6 Â 10 6 cells per ml were infected with Ad5/F11p-SFV-GFP at a MOI of 10 or 25. The cell-virus blends were serially diluted in RPMI-1640 medium containing 10% FCS at a ratio of 1:2, incubated at 37 1C for 6 h and then the cells were resuspended in fresh RPMI-1640 containing 10% FCS. GFP expression was analyzed at 48 h post infection using FACS.
Virus incubation time. U937 cells at a density of 8 Â 10 5 cells per ml were infected with Ad5/F11p-SFV-GFP at a MOI of 25 or 50. At 2, 4, 8, 24 or 48 h post infection, the cells were washed with PBS to remove uninfected Ad5/F11p-SFV-GFP, and then the cells were cultured in fresh complete medium. GFP expression was analyzed 48 h post infection using FACS.
Statistical analysis
Values are presented as the mean ± s.d. One-way analysis of variance followed by the Dunnett post hoc test was used to compare the means of two or more experimental groups. Differences between groups were considered to be significant at P o0.05.
RESULTS
Generation and characterization of the adenovirus-alphavirus hybrid vector Ad5/F11p-SFV-GFP Alphavirus could mediate high levels of gene expression in a wide range of cells, but not in hematopoietic cells. To improve its gene-transduction efficiency, we developed an adenoviral-alphavirus hybrid vector, in which a recombinant SFV replicon sequence is under the transcriptional control of the hematopoietic cellspecific promoter CD11Ap. The adenovirus-alphavirus hybrid virus Ad5/F11p-SFV-GFP (Figure 1a ) was successfully generated in 293Cre4 cells as described in MATERIALS AND METHODS. The presence of the alphavirus replicase NsP genes and reporter gene EGFP were confirmed in the viral genomic DNA of Ad5/F11p-SFV-GFP using RT-PCR (Figure 1b) . The VPs titer of purified Ad5/F11p-SFV-GFP was 6.161 Â 10 11 VP ml À 1 as measured by quantitative PCR, 0.678% of which contained Ad5/F11p-HV. The infection titer (IU), as calculated by the number of GFP-expressing cells in HEK293 cells at 48 h post infection with serial dilutions of the virus, was 6.1 Â 10 10 IU ml À 1 . The VP titer and IU of the control vector Ad5/F11p-GFP were 8.6 Â 10 11 VP ml À 1 and 4.3 Â 10 10 IU ml À 1 , respectively. The ratio between the IU and number of viral physical particles was 1:10 for Ad5/F11p-SFV-GFP and 1:20 for Ad5/F11p-GFP.
Ad5F11p-SFV-GFP mediates high transgene expression in U937 cells through aggregation of redundant subgenomic mRNA The RNA replicase (Rep) complex, encoded by the viral nonstructural genes (NsPs), is the key factor for high expression levels of alphaviral vectors. In our design, the expression of NsPs is promoted by CD11Ap, while the EGFP expression is under transcriptional control of the subgenomic promoter. Our results showed that the expression of EGFP rapidly increased from 32 h to 48 h post infection in Ad5/F11p-SFV-GFP-infected U937 cells (Figure 1c) . To clarify the mechanisms by which Ad5/F11p-SFV-GFP led to high transgene expression, the mRNA expression levels of the NsP genes and EGFP were measured in Ad5/F11p-SFV-GFPinfected U937 cells by quantitative RT-PCR. Expression of EGFP rapidly increased from 24 h to 48 h post infection in Ad5/ F11p-SFV-GFP-infected cells, and was 425-fold higher than the expression of the NsP genes at 48 h post infection in Ad5/ F11p-SFV-GFP-infected cells (Figure 1d) . Expression of EGFP is under the control of the subgenomic promoter in Ad5/F11p-SFV-GFP; therefore, these results indicate that high levels of subgenomic mRNA were expressed in Ad5/F11p-SFV-GFP-infected Gene-transfer efficiency of Ad5/F11p-SFV-GFP in hematopoietic cell lines The human leukemic cell lines K562 (derived from chronic myelogenous leukemia), U937 (promonocytic leukemia), Jurkat (T-cell leukemia) and HL-60 (acute myelogenous leukemia) were selected as target cells to compare the gene-transfer efficiency of Ad5/F11p-SFV-GFP and Ad5/F11p-GFP. As shown in Figure 2a , the gene-transduction ability of Ad5/F11p-SFV-GFP was much higher than Ad5/F11p-GFP in K562, U937 and Jurkat cells. Furthermore, the percentage of GFP-positive HL-60 cells also reached 23.50±0.43% when infected by Ad5/F11p-SFV-GFP at a MOI of 400.
The levels of EGFP transgene expression were evaluated by assessing the relative fluorescence intensity. As shown in Figure 2b , infection of hematopoietic cells with Ad5/F11p-SFV-GFP and Ad5/F11p-GFP at different MOIs increased the expression level of GFP in the cells in a dose-dependent manner. For example, the relative fluorescence intensity of K562 cells infected by Ad5/F11p-SFV-GFP increased from 38.07±0.22 at a MOI of 5 to 462.07 ± 16.74 at a MOI of 50, compared to 3.31 ± 0.06 and 28.00 ± 0.48, respectively, in cells infected with Ad5/F11p-GFP. Compared to Ad5/F11p-GFP, Ad5/F11p-SFV-GFP led to significantly higher levels of GFP expression in K562, U937 and Jurkat cells at each of the MOIs tested. For example, the relative fluorescence intensity of U937 cells infected with Ad5/F11p-SFV-GFP at a MOI of 50 was 21.7-times higher than that of cells infected with Ad5/F11p-GFP.
As described above, Ad5F11p-SFV-GFP mediates high transgene expression through aggregation of redundant subgenomic mRNA. In our design, the production of subgenomic mRNA was regulated by hematopoietic cell-specific promoter CD11Ap, so we detected EGFP expression in non-hematopoietic cells. Compared to that in hematopoietic cells, Ad5/F11p-SFV-GFP could not increase the expression levels of EGFP obviously in non-hematopoietic cells, including PC3M, DU145 and MiapacaII cells, suggesting hematopoietic cell-specific production of subgenomic mRNA (Figure 2c ).
Gene-transduction efficiency of Ad5/F11p-SFV-GFP in Primary leukemic cells The gene-transfer ability of Ad5F11p-SFV-GFP was also assessed in primary leukemic cells isolated from 10 leukemia patients. Table 1 shows the percentage of GFP-positive cells after infection of the primary cells with Ad5/F11p-SFV-GFP or Ad5/F11p-GFP at different MOIs. In general, Ad5/F11p-SFV-GFP led to significantly more effective gene transduction than Ad5/F11p-GFP in both primary lymphoid leukemia cells and primary myeloid leukemia cells. The number of GFP-positive leukemic cells ranged from 9.34-89.63% (median, 28.58%) when infected with Ad5/F11p-SFV-GFP at a MOI of 100, compared to 3.37-44.54% (median, 10.42%) in cells infected with Ad5/F11p-GFP at the same MOI. Additionally, the relative fluorescence intensity of the GFP-positive cells from patient no. 1, who was diagnosed with AML after infection with Ad5/F11p-SFV-GFP at a MOI of 100, was 14-times higher than the cells infected with Ad5/F11p-GFP (data not shown).
These results confirm that Ad5/F11p-SFV-GFP could efficiently transduce and lead to high levels of transgene expression in both hematopoietic cell lines and primary leukemia cells, compared to Ad5/F11p-GFP. Therefore, Ad5/F11p-SFV-GFP combines the high infective ability of Ad5/F11p and the high expression ability of an alphavirus.
Relationship of CD46 expression and infection by Ad5/F11p-SFV-GFP in hematopoietic cells Ad5/F11p is a retargeting adenoviral vector with a chimeric fiber of Ad5 and Ad11p, and has a tropism of Ad11p. Furthermore, the hybrid vector Ad5/F11p-SFV-GFP was developed based on Ad5/F11p. The membrane molecule CD46 is considered to be a receptor for Ad11p. 16, 17 FACS confirmed that the expression of CD46 in hematopoietic cell lines (Figure 3a) was consistent with the gene-transfer ability of Ad5/F11p-SFV-GFP (Figure 2a) .
To investigate the function of CD46 in the infection of malignant hematopoietic cells by Ad5/F11p-SFV-GFP, the effects of blocking the CD46 receptor (using a specific anti-CD46 Ab) on the gene-transduction ability of Ad5/F11p-SFV-GFP was investigated in U937, K562 and Jurkat cells. The gene-transduction ability of Ad5/F11p-SFV-GFP was significantly inhibited in U937, K562 and Jurkat cells pretreated with the anti-CD46 Ab (Figure 3d ). These data demonstrate that CD46 is one of the major receptors that are essential for the process of Ad5/F11p-SFV-GFP infection in malignant hematopoietic cells, consistent with the role of CD46 in cells infected with Ad5/F11p-GFP. 9 However, the expression of CD46 (Figures 3b and c) was inconsistent with the gene-transfer efficiency of Ad5/F11p-SFV-GFP in primary human leukemia cells ( Table 1 ), suggesting that other factors besides CD46 may influence the gene-transduction ability of Ad5/F11p-SFV-GFP in these cells. 17 Optimization of Ad5/F11p-SFV-GFP infection conditions To optimize the infection conditions for Ad5/F11p-SFV-GFP, we focused on two parameters: cell density and viral incubation time. The influence of cell density on gene-transfer efficiency is shown in Figure 4a . In U937 cells infected with Ad5/F11p-SFV-GFP at a MOI of 25, gene-transfer efficiency increased from 33.87±3.42% to 92.85±1.08% and relative fluorescence intensity increased from 4.36±0.73 to 29.13±1.97 as the cell density increased from 2 Â 10 5 cells per ml to 1.6 Â 10 6 cells per ml. Incubation time with the virus is another important parameter for gene-transfer efficiency. In U937 cells infected with Ad5/F11p-SFV-GFP at a MOI of 50, a steady increase in gene-transfer efficiency was observed as incubation time increased from 2 h to 24 h, and then gene transfer declined at an incubation time of 48 h. When U937 cells were infected with Ad5/F11p-SFV-GFP at a MOI of 50, relative fluorescence intensity increased from 28.07 ± 3.16 at 2 h to 118.81 ± 8.33 at 24 h, and then declined to 80.85±4.77 at an incubation time of 48 h (Figure 4b ). Similar trends were observed in K562 cells (data not shown). Prolonged periods of incubation may reduce the efficiency of gene expression by triggering with alphavirus-induced apoptosis. [18] [19] [20] These results suggested that optimal transfer efficiency could be achieved by infection of hematopoietic cells with Ad5/F11p-SFV-GFP at 1.6 Â 10 6 cells per ml for 24 h.
DISCUSSION
Cell-based autologous cancer vaccines offer the promising ability to potentially shift the adaptive immune system of patients with cancer from ignorance or anergy towards cell-mediated immune recognition of cancer cells. Large numbers of cancer cells can easily be isolated from leukemia patients, making these cells an ideal model for autologous patient-derived cell-based autologous vaccine production. 21 To overcome immune tolerance in patients, most cell-based autologous vaccines are modified using immunomodulators in vitro. To date, various approaches have been tested to modify human leukemic cells; [22] [23] [24] retroviral vectors are the most widely used approach. However, retroviral transduction is dependent on the proliferation of the target cells and may lead to safety concerns due to its ability to integrate the viral DNA into host genome. [4] [5] [6] Alphavirus vectors have received considerable attention as they can express high levels of heterologous proteins. 10, 11 To improve the efficiency of gene delivery, several Ad5-based adenoviral-alphavirus hybrid vectors have been developed for cancer therapy and vaccine design. 25, 26 However, the gene-transfer efficiency of Ad5 is relatively low in hematopoietic cells. In this study, we developed an Ad5/F11p-based adenoviral-alphavirus hybrid vector Ad5/F11p-SFV-GFP, which could induce efficient gene transfer into a variety of malignant hematopoietic cells, including cell lines and primary leukemia cells. Although it is necessary for the therapeutic transgenic protein to be expressed at high levels in cancer cells, stable gene expression may not be superior in terms of vaccine efficacy compared with methods that express transgenes for a few days before being irradiated to prevent proliferation. 27 Therefore, hybrid vectors such as Ad5/F11p-SFV-GFP tested in this study might represent promising vectors for gene modifications in cell-based leukemia vaccines. For further evaluation, hybrid vectors will be armed with immunogenes, such as IL-2, CD80, CD40 ligand and so on. Furthermore, we will analysis the therapeutic effect both in vitro and in proper animal models. 
